TGF-β3 ameliorates IL-10-sufficient lupus-prone MRL/Faslpr/lpr (MRL/lpr) mice [59], but the requirement of both TGF-β3 and IL-10 in the regulation of other lupus models induced with a TLR7 agonist [109] implies the importance of considering ICS when designing future therapeutic strategies. Here, TGFB3 is linked to systemic lupus erythematosus.